| Literature DB >> 35478288 |
Dorina Strieth1, Selina Lenz1, Roland Ulber1.
Abstract
Due to the emerging rise of multi-drug resistant bacteria, the discovery of novel antibiotics is of high scientific interest. Through their high chemodiversity of bioactive secondary metabolites, cyanobacteria have proven to be promising microorganisms for the discovery of antibacterial compounds. These aspects make appropriate antibacterial screening approaches for cyanobacteria crucial. Up to date, screenings are mostly carried out using a phenotypic methodology, consisting of cyanobacterial cultivation, extraction, and inhibitory assays. However, the parameters of these methods highly vary within the literature. Therefore, the common choices of parameters and inhibitory assays are summarized in this review. Nevertheless, less frequently used method variants are highlighted, which lead to hits from antimicrobial compounds. In addition to the considerations of phenotypic methods, this study provides an overview of developments in the genome-based screening area, be it in vivo using PCR technique or in silico using the recent genome-mining method. Though, up to date, these techniques are not applied as much as phenotypic screening.Entities:
Keywords: antimicrobial compounds; bioactivity assay; cyanobacteria; in silico screening; in vivo screening
Mesh:
Substances:
Year: 2022 PMID: 35478288 PMCID: PMC8924698 DOI: 10.1002/mbo3.1268
Source DB: PubMed Journal: Microbiologyopen ISSN: 2045-8827 Impact factor: 3.904
Figure 1Schema of the commonly used procedure for the screening of antibacterial compounds from cyanobacteria, LLE, liquid‐liquid extraction; EPS, extracellular polymeric substances.
Overview of the antimicrobial activity of cyanobacterial extracts, as well as extraction parameters (fraction of the cultivation, solvent, and special properties of the extraction), antimicrobial activity assay, and cultivation parameters (culture temperature/media/duration/and light intensity/light‐dark‐rhythm)
| Source | Cyanobacterium strain | Antimicrobial activity against | Cultivation | Extraction | Antimicrobial Assay | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Conditions and duration | Light intensity/light‐dark rhythm | Tested fraction | BM drying | Extraction solvent | Assay type | Parameter | ||||
| Nainangu et al., |
| STY, SA, EC, KP | 25°C, BG‐11 N+; pH 7.4, 30 days | 40–50 µmol Photons/(m²s), 14/10 | Crude extract + fractions | Not stated | 1:1 methanol: chloroform | Disc diffusion + resazurin assay | 37°C, 24 h | |
|
| STY, SA | |||||||||
| Vasudevan et al., |
| EC, SA, BS, VH, VC, PA | Direct sample | Crude extract | Not stated | Methanol | Disc diffusion | 37°C, 24 h | ||
| Yalcin et al., |
| EC, SE, SA, SAG, EF | BG‐11, 25 C, 15 days | 50 µmol photons/(m²s)16/8 | Crude extract | Not stated | Methanol/acetone | Disc diffusion + micro dilution | 24 h | |
| Konstantinou et al., |
| SA | 20°C, BG‐11 medium (+nitrogen) | 20 µmol photons/(m²s)12/12 | Crude extract | FD | 90% methanol | Disc diffusion | 37°C, 48 h | |
|
| SA | |||||||||
|
| SA | |||||||||
|
| SA, PA, EC | |||||||||
|
| SA | |||||||||
| Hassan et al., |
| EC, KS, SE, SA | No temperature control, BG‐11, 20 days | Crude extract | 40°C | 97% ethanol | soxhlet extractor | Well diffusion | 37°C, 24 h | |
| N. Padmini et al., |
| EC, KP | 30°C, ASN‐III medium pH 7,4 | 2500 Lux, 14/8 | Crude extract | 60°C | Chloroform/acetone/dichloromethane/ethyl acetate/petroleum ether | Disc diffusion | 37°C, 24 h | |
| Shishido et al., |
| SA | 20°C, Z8, 21–28 days | 10 µmol photons/(m²s) constant | Crude extract | FD | 1. methanol; 2. dichloromethane/water | Disc diffusion | 35°C–37°C, overnight | |
|
| SA | |||||||||
|
| SA | |||||||||
|
| SA | |||||||||
|
| SA | |||||||||
|
| SA | |||||||||
|
| SA | |||||||||
|
| SA | |||||||||
| Gkelis et al., |
| EC, SA | 20°C–25°C, BG‐11 | 25 µmol Photons/(m²s)12/12 | Crude extract | FD | 90% methanol | Disc diffusion | 37°C, 48 h | |
|
| SA | |||||||||
|
| EC, SA | |||||||||
|
| SA | |||||||||
|
| EC, SA | |||||||||
| Deyab et al., |
| KP, PA, SA | Direct sample | ‐ | Crude extract | Air‐dried | 1. Methanol 2. Petroleum ether (3. Chloroform) | Disc diffusion | 37°C, 24 h | |
| Hemlata et al., 2018 |
| PA, EC, SA | 30°C, BG‐11 pH 8 | 25 µmol Photons/(m²s)12/12 | Crude extract | 50°C | 0.1 M potassium phosphate buffer (pH7.1) | repeated freezing and thawing | Micro dilution | 37°C, overnight, 595 nm |
| Kumar et al., |
| EC | 22°C, BG‐11 | Crude extract | 60°C | Methanol | sonic assisted | Well diffusion | 37°C, 24–48 h | |
|
| EC | |||||||||
|
| EC | |||||||||
| Levert et al., |
| EC, ML | ? | Pure substance | FD | Ethyl acetate | Microdilution | 37°C, 24 h, 630 nm | ||
| Veerabadhran et al., |
| EC | 27°C | 36–45 µmol Photons/(m²s)14/10 | Crude extract | Not stated | 1:1 chlorofom: methanol | Resazurin assay | 37°C;18–24 h, 560/590 nm | |
|
| EC | |||||||||
| Cheel et al., |
| BS | 28°C, 10 days | Partial purified extract | FD | Methanol + seasalt | Micro dilution | 37°C, 16 h | ||
| Pham et al., | various Nostoc sp. Isolates | SA, BS, SF, STY | BG‐11,7–8 weeks | 12/12 | Crude extract | FD | Ethyl acetate/methanol | sonic assisted | Disc diffusion | (4°C, 24 h) 37°C, 24 h |
| Belhaj et al., |
| EC, SA, ML, BA | 25°C, modified BG‐11, 11 days | 100 µmol Photons/(m²s)14/10 | Polysaccharide extract | 45°C | Water | Disc diffusion + MTT assay | (4°C, 2 h) 37°C, 24 h | |
| Strieth et al., |
| EC | 24°C, BG‐11 | 100 µmol Photons/(m²s) | EPS extract | EPS; FD | 0.14 M NaCl+ 0.2 M EDTA | Resazurin assay | ||
| Hamouda Ali & Doumandji, |
| EC, KS, ST, PA | 25°C, 5–6 days | 7.5/10 µmol Photons/(m²s)16/8 | Crude extract | 60°C | Soxhlet extractor | (4°C, 2 h) 37°C, | ||
| 18–24 h | ||||||||||
| Barboza et al., |
| SA (methanol) | 25°C, BG‐11/Conway | 12/12 | Crude extract | FD | Methanol or ethanol | Well diffusion | 37°C, 18–24 h | |
|
| PA (ethanol) | |||||||||
|
| PA (ethanol) | |||||||||
|
| PA (ethanol + methanol) | |||||||||
| Elshouny et al., |
| EC, SAS, SHS, SA, PA | 30°C, Zarrouk/Kuhl, until late exponential phase | Crude extract | 60°C | Methanol, ethanol, ethyl acetate, and chloroform | sonic assisted | Microdilution + well diffusion | 37°C, 24 h, 620 nm | |
| Different isolates, not specified | EA, YE, (BC, LM, ML, PA, SA) | BG‐ 11 agar, 2–3 weeks | Cyano‐bacteria | ‐ | ‐ | Agar inhibition | 37°C, 24 h | |||
| Esquivel‐Hernández et al., |
| SA, PA, EC (polar solvent) | Modified Jourdans, 8 days | Crude extract | Air‐dried | Ammonium acetate 10 mM and ethanol/limonene and ethyl acetate | microwave‐assisted | Disk diffusion | 30°C, 24 h | |
| A. Srivastava et al., |
| EC EN, ST, SB, KP, EA | 28°C, BG‐11 | 14–40 W/m2, 18/6 | Crude extract | FD | Methanol; dissolved in methanol, acetone, DSMO, or diethyl ether | Micro dilution + disk diffusion | 37°C, 24 h | |
|
| EC, SA, EN, ST, SB, KP, EA | |||||||||
|
| EC, SA, SB | |||||||||
|
| EC, EN, ST, SB, KP, EA | |||||||||
|
| EC, EN | |||||||||
|
| EC, SA, EN, EA | |||||||||
| Montalvão et al., |
| EF | 22°C, 23 days | 100 µmol Photons/(m²s)constant | Crude extract | FD | 80% ethanol | |||
| Niveshika et al., |
| EC, PV, PA | 25°C, BG‐11, 40–45 days | 95 µmol Photons/(m²s)14/10 | Pure substance | FD | Methanol | Disk diffusion | 37°C, 24 h | |
| Costa et al., |
| PP | 25°C, Z8 + 20 g/L NaCl, | 30–40 µmol Photons/(m²s)14/10 | Crude extract/fractions | FD | 1:2 methanol: dichloromethane | Microdilution | 25°C, 24 h, 750 nm | |
| Lamprinou et al., |
| SA, SA (MRSA), SA (MSSA), EF, EF(VRE) and EF (VRE) | 23°C, BG‐11/BG‐11 0, 150–200 days | 7 µmol Photons/(m²s) | Lipid fractions | Not dried | Bligh Dyer method (1:2 chloroform/methanol, + chloroform + water) | Disk diffusion + micro dilution | 37°C, 24 h | |
|
| SA, SA (MRSA), SA (MSSA), EF, EF(VRE) and EF (VRE) | Lipid fractions | ||||||||
Abbreviations: BA, B. amyloliquefaciens; BC, B. cereus; BM, Biomass; BS, B. subtilis; EA, E. aerogenes; EC, E. coli; EF, E. faecalis; EN, Enterococcus; FD, freeze‐dried; KP, K. pneumoniae; KS, Klebsiella sp.; LM, L. onocytogenes; PA, P. aeruginosa; PP, Pseudomonas putida; PV, P. vulgaris; SA, S. aureus; SAG, S. agalactiae; SAS, Salmonella sp.; SB, S. boydii; SE, S. epidermidis; SF, S. flexneri; SHS, Shigella sp.; ST, S. typhimurium; STY, S. typhi; VC, V. cholerae; VH, V. harveyi; YE, Y. enterocolitica.
Figure 2Schematic overview of cultivation parameters that can influence the production of antimicrobial compounds. N, nitrogen; S, supernatant; EPS, extracellular polymeric substances; exp., exponential; stat., stationary; µE, mmol photons/(m2s)
Figure 3Different approaches for the usage of genome‐based screening methods for the identification of promising cyanobacteria for novel bioactive substances, using in vivo and in silico tools as well as Mass spectrometry (MS) and nuclear magnetic resonance (NMR) for purification